New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 21, 2012
09:25 EDTRHT, NKE, CEMI, HALO, PFE, RIMM, WAG, TSPTOn The Fly: Pre-market Movers
HIGHER AFTER EARNINGS: Red Hat (RHT), up 5.4%... Nike (NKE), up 3%... ALSO HIGHER: Chembio Diagnostics (CEMI), up 20.7% after receiving FDA approval for its rapid HIV test... Halozyme (HALO), up 17.4% after entering a development collaboration with Pfizer (PFE)... Ameristar Casinos (ASCA), up 17% after agreeing to be acquired by Pinnacle Entertainment (PNK) for $26.50 per share... LOWER AFTER EARNINGS: Research in Motion (RIMM), down 16.3%... Walgreen (WAG), down 1.7%... ALSO LOWER: Transcept (TSPT), down 14.7% after Phase 2 trial of OCD drug misses primary endpoint.
News For RHT;NKE;CEMI;HALO;PFE;RIMM;WAG;TSPT From The Last 14 Days
Check below for free stories on RHT;NKE;CEMI;HALO;PFE;RIMM;WAG;TSPT the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
August 22, 2014
14:19 EDTPFEViiV Healthcare receives FDA approval for HIV-1 treatment Triumeq
Subscribe for More Information
13:45 EDTWAGWalgreen pharmacy database fails after system update, DJ reports
Subscribe for More Information
05:44 EDTWAGStocks with implied volatility below IV index mean; SNDK WAG
Stocks with implied volatility below IV index mean; SanDisk (SNDK) 23, Walgreen (WAG) 20 according to iVolatility.
August 21, 2014
13:32 EDTPFEBristol-Myers, Pfizer announce approval of Eliquis for treatment of DVT, PE
Subscribe for More Information
11:47 EDTWAGWalgreen upgraded at BofA/Merrill
Subscribe for More Information
11:24 EDTNKEUnder Armour offered Durant $265M-$285M contract, ESPN reports
Subscribe for More Information
11:09 EDTWAGWalgreen upgraded to Neutral from Underperform at BofA/Merrill
09:54 EDTPFEPotential Pfizer, AstraZeneca deal seen around year-end, Reuters says
Investors and analysts see Pfizer (PFE) making another attempt to acquire AstraZeneca (AZN) around year-end, even though talks between the two can resume on August 26 per British takeover rules, Reuters reports. Reference Link
08:02 EDTPFEPfizer initiates U.S. EAP for palbociclib.
Pfizer announced that the company has initiated a multi-center, open-label expanded access program in the U.S. for palbociclib. Through the program, palbociclib is being made available for use in combination with letrozole for post-menopausal women with hormone receptor positive human epidermal growth factor receptor 2 negative advanced breast cancer for whom letrozole is considered appropriate therapy.
07:55 EDTPFEActavis volatility expected to move on Pfizer considering new target report
Actavis (ACT) volatility is expected to move on Pfizer (PFE) considering other overseas alternatives, Bloomberg reports. Overall option implied volatility of 27 is near its 26-week average of 31 according to Track Data, suggesting decreasing price movement.
07:47 EDTPFEPfizer looking at new targets, including Actavis, Bloomberg reports
While it weighs another attempt to acquire AstraZeneca (AZN), Pfizer is considering other overseas alternatives, including Actavis (ACT), Bloomberg reports, citing people familiar with the matter. Pfizer prefers to reach a deal with AstraZeneca, and a move on another company is unlikely "anytime soon," Bloomberg adds, citing its sources. Shares of Actavis are rising 3%, or $6.65, to $230.01 in pre-market trading, while AstraZeneca is up 2% to $72.59. Reference Link
06:00 EDTWAGStocks with implied volatility below IV index mean; TWX WAG
Subscribe for More Information
August 20, 2014
08:09 EDTWAGWalgreen pressured CFO, pharmacy chief to leave, WSJ reports
Subscribe for More Information
08:03 EDTPFEBristol-Myers Pfizer to present new Eliquis data
Subscribe for More Information
06:00 EDTWAGStocks with implied volatility below IV index mean; SEAS WAG
Subscribe for More Information
August 19, 2014
06:01 EDTWAGStocks with implied volatility below IV index mean; SEAS WAG
Subscribe for More Information
August 18, 2014
11:41 EDTPFECubist rises after report sparks takeover interest speculation
Subscribe for More Information
08:01 EDTPFEPfizer announces submission of Palbociclib NDA to FDA
Pfizer announced it has completed the submission of a New Drug Application to the United States Food and Drug Administration for palbociclib. This NDA requests FDA approval of palbociclib, in combination with letrozole, for the treatment of postmenopausal women with estrogen receptor positive, human epidermal growth factor receptor 2 negative advanced breast cancer who have not received previous systemic treatment for their advanced disease. The submission is based on the final results of PALOMA-1, a randomized, Phase 2 trial comparing palbociclib plus letrozole versus letrozole alone in this population of patients. Palbociclib received Breakthrough Therapy designation from the FDA in April 2013, for the first-line systemic treatment of women with advanced or metastatic ER+, HER2- breast cancer. This designation was based on interim data from the PALOMA-1 trial. The FDA has a 60-day filing review period to determine whether the NDA is complete and acceptable for filing. Pfizer will communicate the Agency’s decision.
07:57 EDTPFECambridge Healthtech Institute to hold a summit
6th Annual Bioprocessing Summit to be held in Boston on August 18-22.
06:04 EDTWAGStocks with implied volatility below IV index mean; SEAS WAG
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use